2023-11-10T15:46:50-06:00 2022-12-31 346565596 ERNST & YOUNG US LLP 18101 VON KARMAN AVENUE SUITE 1700 IRVINE CA 92612 990 2022-01-01 954772979 CALIFORNIA HEART CENTER FOUNDATION CALI 3102488327 8670 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 JON KOBASHIGAWA MD PRESIDENT 3102488327 2023-11-10 1 JON KOBASHIGAWA MD 999009999 1 KARA ADAMS P00023315 9497942300 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z JON KOBASHIGAWA MD 8670 WILSHIRE BOULEVARD SUITE 301 BEVERLY HILLS CA 90211 3147736 0 X WWW.CALHEART.ORG X 2000 CA PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. 5 3 0 0 0 0 2100269 2935423 239244 212313 0 0 0 0 2339513 3147736 0 0 0 0 1668259 2109018 0 0 0 470643 594106 2138902 2703124 200611 444612 372009 932998 228408 344785 143601 588213 X THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. 0 0 2444497 0 212313 THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2022: SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "CONSENSUS CONFERENCE: THE EVOLVING USE OF BIOMARKERS TO PERSONALIZE CARE IN HEART TRANSPLANTATION" (VIRTUAL)ENDORSED BY THE AMERICAN SOCIETY OF TRANSPLANTATION AND ORGANIZED AND CHAIRED BY DR. KOBASHIGAWA, THE CONSENSUS CONFERENCE ON THE EVOLVING USE OF BIOMARKERS TO PERSONALIZE CARE IN HEART TRANSPLANTATION WAS HELD VIRTUALLY ON JANUARY 27-28, 2022. ATTENDED BY 30 EXPERTS REPRESENTING HEART TRANSPLANT PROGRAMS IN ALL REGIONS OF THE UNITED STATES, THE CONFERENCE WAS DESIGNED TO SERVE AS A PLATFORM TO FURTHER BUILD CONSENSUS WITHIN THE HEART TRANSPLANT COMMUNITY REGARDING THE OPTIMAL FRAMEWORK TO IMPLEMENT BIOMARKERS INTO MANAGEMENT PROTOCOLS AND TO IMPROVE BIOMARKER DEVELOPMENT, VALIDATION AND CLINICAL UTILITY. A WHITE PAPER ON THE CONFERENCE IS CURRENTLY PENDING PUBLICATION IN THE AMERICAN JOURNAL OF TRANSPLANTATION.* "CONSENSUS CONFERENCE ON COMBINED HEART/LIVER TRANSPLANTATION" (VIRTUAL)ENDORSED BY THE AMERICAN SOCIETY OF TRANSPLANTATION AND ORGANIZED AND CHAIRED BY DR. KOBASHIGAWA, THE CONSENSUS CONFERENCE ON COMBINED HEART/LIVER TRANSPLANTATION WAS HELD VIRTUALLY ON JUNE 10TH, 2022. ATTENDED BY 60 EXPERTS REPRESENTING HEART TRANSPLANT PROGRAMS IN ALL REGIONS OF THE UNITED STATES, CONFERENCE WAS DESIGNED AS A FIRST STEP IN DEVELOPING NEEDED GUIDELINES FOR THE INTERDISCIPLINARY CRITERIA FOR LIVER TRANSPLANTATION IN THE COMBINED HEART/LIVER TRANSPLANT CANDIDATE, EVALUATING THE CURRENT ALLOCATION OF LIVERS TO FOLLOW THE HEART FOR THE HEART/LIVER TRANSPLANT RECIPIENT AND RECOMMENDING STANDARDIZED CARE FOR THE COLLABORATIVE MANAGEMENT OF HEART/LIVER TRANSPLANT RECIPIENTS. THE CONFERENCE WAS PRECEDED BY A SERIES OF MONTHLY "EXPERT WORK GROUP" MEETINGS WITH KEY THOUGHT LEADERS IN BOTH LIVER TRANSPLANTATION AND HEART TRANSPLANTATION. THE WORK GROUP WAS TASKED WITH IDENTIFYING AND ELUCIDATING IMPORTANT ISSUES, INCLUDING A REVIEW OF CURRENT PRACTICES, A DISCUSSION OF RELEVANT PUBLISHED RESEARCH AND OUTLINING RECOMMENDATIONS FOR COMMUNITY DISCUSSION. THEIR WORK INFORMED THE VIRTUAL CONSENSUS CONFERENCE WHICH WAS OPEN TO THE BROADER COMMUNITY. A WHITE PAPER ON THE CONFERENCE IS CURRENTLY BEING DRAFTED FOR PUBLICATION.* SUCCESS WITH FAILURE: BEYOND THE BASICS - LECTURES SERIES (VIRTUAL)PLANNED AS THREE 90-MINUTE LUNCH-TIME FORUMS DURING THE MONTH OF FEBRUARY 2022, THIS VIRTUAL PROGRAM FEATURED PRESENTATIONS ON TOPICS RELATED TO THE DIAGNOSIS AND TREATMENT OF HEART FAILURE, TRANSPLANTATION, AND MECHANICAL CIRCULATORY SUPPORT USING A CASE-BASED FORMAT AND ALLOWING FOR GENEROUS Q&A TIME. SESSIONS HAD AN AVERAGE OF 120 PARTICIPANTS.* "THOMAS D. GORDON VISITING PROFESSOR IN ADVANCED HEART DISEASE"THIS ANNUAL VISITING PROFESSORSHIP HAS CONTINUED TO BE SPONSORED AND ORGANIZED BY DR. KOBASHIGAWA. THIS YEAR WE HAD THE HONOR OF HOSTING DR. JOHN WALLWORK, RENOWNED CARDIOTHORACIC SURGEON AND CHAIRMAN OF THE ROYAL PAPWORTH HOSPITAL IN THE UNITED KINGDOM. THIS VISIT, HELD OCTOBER 10TH-11TH, 2022, INCLUDED A GRAND ROUNDS LECTURE, ONE TO ONE FACULTY MEETINGS AND A FELLOWS' PROFESSIONAL DEVELOPMENT DISCUSSION. DR. WALLWORK'S LECTURE ON "PIGS MIGHT FLY! HISTORY OF XENOTRANSPLANTATION" WAS EXTREMELY WELL RECEIVED.* SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR. JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO STUDENTS FOR THE SUMMER OF 2022. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WERE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES STUDENTS FROM:CENTRAL MICHIGAN UNIVERSITY, COLLEGE OF MEDICINEPOMONA COLLEGE, CLAREMONTUNIVERSITY OF CALIFORNIA, LOS ANGELESUNIVERSITY OF CALIFORNIA, RIVERSIDEUNIVERSITY OF CHICAGOUNIVERSITY OF HAWAII SCHOOL OF MEDICINEUNIVERSITY OF WISCONSINWESLEYAN UNIVERSITY* HEART TRANSPLANT JOURNAL CLUBSJOURNAL CLUBS CONTINUE TO BE HELD IN A VIRTUAL FORMAT AND HAVE MAINTAINED STRONG PARTICIPATION, WITH AN AVERAGE ATTENDANCE OF 25 PEOPLE AT EACH SESSION. THE FOLLOWING SESSION(S) HAVE BEEN IMPLEMENTED OR SCHEDULED: MAY 21ST, 2022 - 4:00PM - 5:00PM "PREVALENCE AND CUMULATIVE RISK OF FAMILIAL IDIOPATHIC DILATED CARDIOMYOPATHY" PRESENTER: DR. HILARY SHAPIRO SEPTEMBER 29TH, 2022 - 4:00PM - 5:00PM "DAPAGLIFLOZIN IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION" PRESENTER: DR. MAXINE STACHEL, MD CLINICAL RESEARCH:THIS SECTION IS FORMATTED BY CATEGORY; STUDY NAME; PRINCIPAL INVESTIGATOR (PI). 2444497 1 1 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 2 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 5 3 0 0 0 0 1 1 1 1 1 0 0 0 1 1 1 0 0 0 1 0 CA X DEBBIE BOTTEN 3104238473 6500 WILSHIRE BLVD 15TH FLOOR LOS ANGELES CA 90048 EDUARDO MARBAN MD DIRECTOR 1.00 60.00 X 0 3771428 92469 THOMAS D GORDON DIRECTOR 1.00 3.00 X 0 111150 0 JON KOBASHIGAWA MD PRESIDENT 2.00 0.00 X X 0 0 0 MICHELE HAMILTON TREASURER 2.00 0.00 X X 0 0 0 JAIME MORIGUCHI MD DIRECTOR 1.00 0.00 X 0 0 0 CHRISTINE SUMBI SECRETARY 40.00 0.00 X 0 247720 30653 IRINA COZIANU RESEARCH OPER. MANAGER 40.00 0.00 X 0 155681 38610 VENISE STRAND PROGRAM MANAGER 40.00 0.00 X 0 129056 33826 PHYLLIS KATZ EXECUTIVE ASSISTANT 40.00 0.00 X 0 102604 20386 MARIA M THOTTAM FORMER HIGHEST COMPENSATED EMPLOYEE 0.00 40.00 X 0 112141 17681 0 4629780 233625 0 1 1 0 0 2935423 2935423 EDUCATIONAL PROGRAMS 611430 212313 212313 212313 3147736 212313 0 0 252345 252345 1540016 1540016 74744 74744 94719 94719 147194 147194 922 645 277 12800 11520 1280 439835 439835 94509 89784 4725 29438 29438 BANK CHARGES 4862 4862 DUES & SUBSCRIPTIONS 2916 2916 MEALS 2539 2539 MOVING/STORAGE 2374 2374 3911 3911 2703124 2444497 258627 0 271613 306503 396 398 581134 115037 0 466097 100000 160000 372009 932998 228408 344785 228408 344785 X 143601 588213 143601 588213 372009 932998 444612 0 X 0 0 0 X 1603657 1944292 2136097 2100269 2935423 10719738 1603657 1944292 2136097 2100269 2935423 10719738 10719738 10719738 1278059 1.00000 1.00000 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 473456 7359 466097 70594 70594 0 37084 37084 0 466097 OTHER RECEIVABLES 160000 160000 0 1 0 0 0 0 0 0 0 EDUARDO MARBAN MD DIRECTOR 0 2447723 0 560731 0 762974 0 64760 0 27709 0 3863897 0 0 CHRISTINE SUMBI SECRETARY 0 202688 0 36504 0 8528 0 20815 0 9838 0 278373 0 0 IRINA COZIANU RESEARCH OPER. MANAGER 0 133656 0 17630 0 4395 0 13180 0 25430 0 194291 0 0 VENISE STRAND PROGRAM MANAGER 0 113418 0 15484 0 154 0 7641 0 26185 0 162882 0 0 MARIA M THOTTAM FORMER HIGHEST COMPENSATED EMPLOYEE 0 111306 0 0 0 835 0 11155 0 6526 0 129822 0 0 PART I, LINE 3 PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, SECTION B LINE 15B. PART I, LINE 4B THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. THE FOLLOWING DIRECTOR AND OFFICER RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2022: CHRISTINE SUMBI 7,462 EDUARDO MARBAN, MD 623,698 FORM 990, PART III, LINE 4A (CONTINUED) AMYLOIDOSIS; PHASE 3 GLOBAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION-682884 IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR CM); PATEL AMYLOIDOSIS; APOLLO-B: A STUDY TO EVALUATE PATISIRAN IN PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY); PATEL AMYLOIDOSIS; A PHASE 3 GLOBAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ION-682884 IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY; PATEL AMYLOIDOSIS; EIDOS -AG310-301 (A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF AG10 IN SUBJECTS WITH SYMPTOMATIC TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTRIBUTE-CM TRIAL)); PATEL AMYLOIDOSIS; CARDIAC AMYLOIDOSIS REGISTRY STUDY (MULTI-CENTER); PATEL AMYLOIDOSIS; AMYLOIDOSIS SURVEY; PATEL HEART FAILURE; A DOUBLE-BLIND, RANDOMIZED, SHAM-PROCEDURE-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF ALLOGENEIC MESENCHYMAL PRECURSOR CELLS (REXLEMESTROCEL-L) IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION OF EITHER ISCHEMIC OR NONISCHEMIC ETIOLOGY; CHANG HEART FAILURE; BARIATRIC SURGERY AND HEART FAILURE; HAMILTON HEART FAILURE; REDUCING LUNG CONGESTION SYMPTOMS USING THE V-WAVE SHUNT IN HEART FAILURE (RELIEVE HF); HAMILTON HEART FAILURE; RISK FACTORS AND OUTCOMES IN ADVANCED HEART DISEASE; KOBASHIGAWA HEART FAILURE; DCM PRECISION MEDICINE STUDY; KRANSDORF HEART FAILURE; DILATED CARDIOMYOPATHY PRECISION MEDICINE STUDY - CARDIAC MRI SUBSTUDY; KRANSDORF HEART FAILURE; A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF IN-HOSPITAL INITIATION OF DAPAGLIFLOZIN ON CLINICAL OUTCOMES IN PATIENTS WHO HAVE BEEN STABILIZED DURING HOSPITALIZATION FOR ACUTE HEART FAILURE ; PATEL HEART TRANSPLANT; CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE PORTABLE ORGAN CARE SYSTEM (OCS) HEART FOR RESUSCITATION, PRESERVATION AND ASSESSMENT OF HEARTS FROM DONORS AFTER CIRCULATORY DEATH (DCD HEART TRIAL); ESMAILIAN HEART TRANSPLANT; THE PORTABLE ORGAN CARE SYSTEM (OCS) HEART FOR RESUSCITATION, PRESERVATION AND ASSESSMENT OF HEARTS FROM DONORS AFTER CIRCULATORY DEATH CONTINUED ACCESS PROTOCOL (OCS DCD HEART CAP); ESMAILIAN HEART TRANSPLANT; ORGAN CARE SYSTEM (OCS) HEART SYSTEM: HEART EXPAND CONTINUED ACCESS PROTOCOL (CAP); ESMAILIAN HEART TRANSPLANT; RANDOMIZED TRIAL TO COMPARE THE SHERPAPAK DEVICE VS COLD STORAGE OF DONOR HEARTS IN TRANSPLANTATION: A PILOT STUDY; ESMAILIAN HEART TRANSPLANT; THE FREQUENCY AND SIGNIFICANCE OF BLOOD TYPE A1 DONORS TO NON-A1 SUBGROUP RECIPIENTS IN HEART TRANSPLANTATION; KITTLESON HEART TRANSPLANT; PROSPECTIVE SURVEY STUDY; KOBASHIGAWA HEART TRANSPLANT; ATG (A PILOT RANDOMIZED STUDY TO ASSESS THE EFFECT AND SAFETY PROFILE OF THYMOGLOBULIN IN PRIMARY CARDIAC TRANSPLANT RECIPIENTS: A 12-MONTH, SINGLE CENTER, RANDOMIZED, OPEN-LABEL STUDY OF EFFICACY COMPARING IMMEDIATE TREATMENT WITH AND WITHOUT THYMOGLOBULIN 1.5 MG/KG/D FOR 5 CONSECUTIVE DAYS IN HEART TRANSPLANT RECIPIENTS); KOBASHIGAWA HEART TRANSPLANT; SHORE (SURVEILLANCE HEARTCARE OUTCOMES REGISTRY); KOBASHIGAWA HEART TRANSPLANT; COMPUTER ASSISTED CARDIAC HISTOLOGIC EVALUATION; KOBASHIGAWA HEART TRANSPLANT; TARGETING INFLAMMATION AND ALLOIMMUNITY IN HEART TRANSPLANT RECIPIENTS WITH TOCILIZUMAB; KOBASHIGAWA AND PATEL HEART TRANSPLANT; INFILTRATING B CELLS IN CARDIAC ALLOGRAFT VASCULOPATHY; KRANSDORF HEART TRANSPLANT; IMMUNOLOGIC RISK STUDY; KRANSDORF PULMONARY HYPERTENSION; RIOCIGUAT USERS REGISTRY - THE ROAR REGISTRY; HAGE PULMONARY HYPERTENSION; RIN-PH-304: PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INHALED TREPROSTINIL IN PATIENTS WITH PULMONARY HYPERTENSION DUE TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (PH-COPD); HAGE PULMONARY HYPERTENSION; AN OBSERVATIONAL STUDY TO CHARACTERIZE PATIENT GLOBAL IMPRESSION QUESTIONS FOR ACTIVITY-INDUCED SYMPTOMS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION; HAGE HEART TRANSPLANT; ARTORIA STUDY: AN OBSERVATIONAL STUDY REGARDING THE OUTCOME OF ADULT PATIENTS WITH CONGENITAL HEART DISEASE (ACHD) OR INHERITED CARDIOMYOPATHIES UNDERGOING HEART OR HEART/LUNG TRANSPLANTATION; KOBASHIGAWA AMYLOIDOSIS; ALYNAM - ALN-TTR02-014 EXPANDED ACCESS PROTOCOL TO PROVIDE PATISIRAN TO PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR AMYLOIDOSIS) WITH CARDIOMYOPATHY; PATEL HEART FAILURE; NOVONORDISK NN6019-4940: EFFICACY AND SAFETY OF NNC6019-0001 AT TWO DOSE LEVELS IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR CM); COLE PULMONARY HYPERTENSION; CADENCE - A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF SOTATERCEPT VERSUS PLACEBO FOR THE TREATMENT OF COMBINED POSTCAPILLARY AND PRECAPILLARY PULMONARY HYPERTENSION (CPC-PH) DUE TO HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF); HAGE HEART FAILURE; G-COR STUDY: GLOBAL CARDIO ONCOLOGY REGISTRY PROTOCOL; NIKOLOVA FORM 990, PART IV, LINE 12 THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/22 AND 6/30/23 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/22. FORM 990, PART VI, SECTION A, LINE 6 CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7A CEDARS-SINAI MEDICAL CENTER, AS THE SOLE CORPORATE MEMBER, ELECTS BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. FORM 990, PART VI, SECTION A, LINE 7B RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX-EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; AND (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. FORM 990, PART VI, SECTION B, LINE 12C CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15B THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S OFFICERS AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT WITH RESPECT TO SUCH ISSUES. THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S OFFICERS AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT, AND ANY OTHER ADVISORS IT DEEMS NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 951644600 ACUTE-CARE, TEACHING AND RESEARCH HOSPITAL CA 501(C)(3) LINE 3 CEDARS-SINAI HEALTH SYSTEM 0 CEDARS-SINAI MEDICAL CARE FOUNDATION 6500 WILSHIRE BLVD 15TH FLOOR LOS ANGELES CA 90048 954457756 PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH CA 501(C)(3) LINE 12A, I CEDARS-SINAI MEDICAL CENTER 1 KERLAN-JOBE ORTHOPAEDIC FOUNDATION 6801 PARK TERRACE 500 LOS ANGELES CA 90045 954707606 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC MEDICINE CA 501(C)(3) LINE 7 CEDARS-SINAI MEDICAL CARE FOUNDATION 1 SANTA MONICA ORTHOPAEDIC & SPORTS MED RESEARCH FDN 2020 SANTA MONICA BLVD 4TH FLR SANTA MONICA CA 90404 954789926 EDUCATION AND RESEARCH RELATED TO ORTHOPAEDIC AND NEUROLOGIC CONDITIONS CA 501(C)(3) PF CEDARS-SINAI MEDICAL CARE FOUNDATION 1 CFHS HOLDINGS INC 4650 LINCOLN BLVD MARINA DEL REY CA 90292 201645949 HEALTH SERVICES CA 501(C)(3) LINE 3 CEDARS-SINAI MEDICAL CENTER 1 CEDARS-SINAI HEALTH SYSTEM 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 300990905 SUPPORT SPECIFIED NONPROFIT HEALTHCARE ORGANIZATIONS CA 501(C)(3) LINE 12C, III-FI N/A 0 TORRANCE HEALTH ASSOCIATION 3330 LOMITA BLVD TORRANCE CA 90505 330073515 HEALTH SERVICES CA 501(C)(3) LINE 12B, II CEDARS-SINAI HEALTH SYSTEM 1 TORRANCE MEMORIAL MEDICAL CENTER HEALTH CARE FOUNDATION 3330 LOMITA BLVD TORRANCE CA 90505 953528452 FUNDRAISING CA 501(C)(3) LINE 7 TORRANCE HEALTH ASSOCIATION 1 TORRANCE MEMORIAL MEDICAL CENTER 3330 LOMITA BLVD TORRANCE CA 90505 951644042 HEALTH SERVICES CA 501(C)(3) LINE 3 TORRANCE HEALTH ASSOCIATION 1 CEDARS SINAI INTELLECTUAL PROPERTY COMPANY 8700 BEVERLY BOULEVARD LOS ANGELES CA 90048 871097792 MANAGEMENT AND LICENSING OF INTELLECTUAL PROPERTY ASSETS CA 501(C)(3) 12A, I CEDARS-SINAI MEDICAL CENTER 1 PASADENA HOSPITAL ASSOCIATION LTD 100 WEST CALIFORNIA BLVD PASADENA CA 91105 951644036 HEALTH SERVICES CA 501(C)(3) LINE 3 CEDARS-SINAI HEALTH SYSTEM 1 HUNTINGTON MEDICAL FOUNDATION 100 WEST CALIFORNIA BLVD PASADENA CA 91105 954434428 HEALTH SERVICES CA 501(C)(3) LINE 3 PASADENA HOSPITAL ASSOCIATION LTD 1 CEDARS SINAI HEALTH VENTURES 8721 BEVERLY BLVD LOS ANGELES CA 90048 883506667 MANAGEMENT OF HEALTH INNOVATIONS CA 501(C)(3) 12A, I CEDARS-SINAI MEDICAL CENTER 1 ENDOSCOPY CENTER OF SANTA MONICA LLC 12400 WILSHIRE BLVD SUITE 100 LOS ANGELES CA 90025 113652210 ENDOSCOPIES AND RELATED PROCEDURES CA N/A 0 0 ISS ASC HOLDINGS LLC 6500 WILSHIRE BLVD 15TH FLOOR LOS ANGELES CA 90048 471890805 INVESTMENT IN HEALTHCARE SERVICES CA N/A 0 0 CS-BH ASC HOLDINGS LLC 450 N ROXBURY DR SUITE 602 BEVERLY HILLS CA 90210 812246488 HOLDING COMPANY CA N/A 0 0 INTERNATIONAL SPINE & ORTHOPEDIC INSTITUTE LLC 8500 W 110TH ST OVERLAND PARK KS 66210 263738893 SPINE AND ORTHOPEDIC INSTITUTE DE N/A 0 0 SANTA MONICA IMAGING GROUP LLC 6500 WILSHIRE BLVD 15TH FLOOR LOS ANGELES CA 90048 820760657 IMAGING CENTER CA N/A 0 0 TORRANCE MEMORIAL SURGICAL CENTER LLC I 23560 CRENSHAW BLVD SUITE 104 TORRANCE CA 90505 465259260 OUTPATIENT SURGICAL SERVICES CA N/A 0 0 3565 DEL AMO ASSOCIATES A CALIFORNIA LIMITED PARTNERSHIP 5017 CARMEN STREET TORRANCE CA 90503 330554737 RENTAL REAL ESTATE CA N/A 0 0 90210 ASC VENTURE LLC 450 N ROXBURY DR SUITE 602 BEVERLY HILLS CA 90210 134341801 AMBULATORY SURGERY CENTER CA N/A 0 0 HUNTINGTON AMBULATORY SURGERY CENTER LLC 625 S FAIR OAKS AVE NO 380 PASADENA CA 91105 273922007 AMBULATORY SURGERY CENTER CA N/A 0 0 ABCENTRA LLC 2390 CRENSHAW BLVD 202 TORRANCE CA 90501 202327127 RESEARCH AND DEVELOPMENT DE N/A 0 0 TIA-CEDARS MANAGEMENT SERVICES ORGANIZATION LLC 548 MARKET ST 45295 SF CA 94104 884206382 INVESTMENT IN HEALTHCARE SERVICES CA N/A 0 0 OPTIMATRIX HEALTH SOLUTIONS INC 8700 BEVERLY BLVD LOS ANGELES CA 90048 954522779 INACTIVE CA N/A C 1 OTOHARMONICS CORPORATION PO BOX 272 WILMINGTON DE 19899 461119421 INACTIVE DE N/A C 1 CONGRESS SERVICES CORPORATION 100 WEST CALIFORNIA BLVD PASADENA CA 91105 953978299 MANAGEMENT SERVICES CA N/A C 1 GRAVIDAS DIAGNOSTICS INC 8721 BEVERLY BLVD LOS ANGELES CA 90048 872085657 MEDICAL EQUIPMENT AND SUPPLIES MANUFACTURING DE N/A C 1 THIRD STREET INSURANCE COMPANY (SAC) LTD PO BOX HM 1024 HAMILTON HM DX BD 981678749 CAPTIVE INSURANCE BD N/A C 1 TRIAN PARTNERS II LTD LANDMARK SQUARE WEST BAY ROAD PO GRAND CAYMAN CJ KY1-9006 INVESTMENTS CJ N/A C 1 LIQUID LOAN OPPORTUNITIES FUND LP PO BOX 309 UGLAND HOUSE GRAND CAYMAN CJ KY1-1104 980693063 INVESTMENTS CJ N/A C 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0